Clinical Insight Bundles

Extraordinary insights from routine,
existing EHR and clinical lab data

Lower GI and colorectal disorders

EarlySign’s LGI Flag™ is a decision support tool helping healthcare clients identify patients at high risk for having lower GI disorders, as determined using only blood test results, age, and gender. LGI Flag is associated with changes in blood patters related (mostly) to chronic occult GI bleeding, and typically spots those needing greater assessment, sometimes months before clinical signs appear.

Prediabetes to diabetes (“Pre2D™”) AlgoMarker™

This ML-based software solution identifies prediabetic patients at high risk for progressing to Type 2 Diabetes (T2D) within 12 months using only existing, routine blood test results and other parameters such as age, gender, and BMI.

lung cancer icon

Lung Cancer

Identifies individuals at high risk for having Non-Small-Cell Lung Cancer (NSCLC) using routine, existing clinical labs, smoking history, demographic, and EHR data.

diabetes suite

Diabetes

EarlySign’s suite of diabetes-related solutions helps healthcare systems with early detection, potential delay, and prevention of Type 2 diabetes, as well as of downstream diabetic complications like chronic kidney disease (CKD) and coronary artery disease (CAD).
More than 84 million adults in the U.S. have prediabetes, and most remain undiagnosed.

Preventing or delaying their progression to diabetes can help:

  • Prevent downstream complications and comorbidities
  • Enhance quality of life
  • Lessen care burdens

With our suite of diabetes related AlgoMarkers™, we help healthcare teams to:

  • Predict and stratify patients at risk with high accuracy
  • Focus resources on patients at highest risk
  • Create opportunities for timely intervention

Diabetes to CKD AlgoMarker™

Diabetes to CKD AlgoMarker™ identifies patients with T2D at high risk forprogressing to chronic kidney disease (CKD) stages 2-4 within 3 years using basic demographic data, routine lab results, diagnostic codes, and drug information

Flu

The CDC estimates up to 43 million flu cases (and 61,000 deaths) annually in the US alone. This led EarlySign to develop our newest AlgoMarker, focused on increasing flu vaccination coverage by enabling healthcare systems to strengthen prevention efforts for those populations at highest risk to develop flu-related complications if infected.

COVID-19 Complications

EarlySign’s COVID Complications AlgoMarker™ identifies individuals at increased risk for having COVID-19 complications. With the goal of prioritizing patients for COVID-19 testing and treatment, this new AlgoMarker aids in triaging patients by reducing chart review time to determine whether they are potentially at high risk for hospitalization, complications, and mortality.

Other clinical insight bundles

Contact Us

Are you looking to solve high-burden disease challenges?

Talk with us today
Medial Earlysign logo
Linkedin
Twitter
Facebook

Solutions

Technology

Knowledge Center

Who We Serve

About Us

Knowledge Center

About Us

Copyright © Medial EarlySign 2020 | All rights reserved